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Abstract  
Introduction: Acute tumor lysis syndrome (ATLS) and hepatic failure are fatal complications that can occur in patients with hepatocellular 
carcinoma (HCC) who undergo transarterial chemoembolization (TACE). 
Presentation of Case: We report the case of a 78-year-old man with HCC who had successive ATLS and hepatic failure after the first course of 
TACE. He succumbed due to rapid deterioration of his condition. 
Conclusion: We therefore concluded that awareness of the risks of ATLS and hepatic failure before administration of TACE is crucial in patients 
with HCC. 
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Introduction 
Hepatocellular carcinoma (HCC) is one of the 
common human neoplasm worldwide. Currently, 
transarterial chemoembolization (TACE) is the most 
common approach for the management of HCC 
without curative option. Although TACE is an 
effective modality for unresectable HCC, there are 
several potential side effects such as hepatic failure, 
internal bleeding, liver abscess, biliary tract injury, 
renal failure, and rarely, acute tumor lysis syndrome 
(ATLS) [1].  
ATLS is characterized by the release of 
intracellular components into the bloodstream due to 
massive lysis of malignant cells [2]. The condition is 
associated with a rapidly growing neoplasm. 
Infrequently, it can occur in patients with HCC [1, 
3-7]. The incidence of post-TACE hepatic failure has 
varied from 2.1% to 60%. This variation may be due 
to different definitions of hepatic failure [8]. Most 
studies suggest that a poor liver reserve before 
TACE is the main determinant in development of 
hepatic failure after TACE. 
Here, we present a case of HCC with successive 
ATLS and hepatic failure after the first course of 
TACE. We also review other reports of ATLS and 
hepatic failure in HCC that were retrieved from the 
MEDLINE database. 
Case Presentation 
A 78-year-old retired businessman was admitted to 
our hospital after experiencing progressive 
abdominal fullness for one month. He had no past 
history of viral hepatitis B, C or alcohol 
consumption. He had a fair appetite but had lost 5 
kilograms in the past 3 months. Initially, he went to a 
local clinic where he received abdominal sonography 
which revealed multiple liver tumors. Then he was 
referred to our hospital for further evaluation and 
management. 
On physical examination after admission, the 
patient’s body temperature was 36℃, heart rate was 
80 beats per minute, blood pressure was 124/85 ㎜
Hg, and respiratory rate was 14 breaths per minute 
under normal conditions. There were no icteric 
sclera, yellowish skin discoloration, gynecomastia, 
spider angiomata, palmar erythma or leg edema. 
Laboratory data demonstrated serum aspartate 
aminotransferase (AST) 92 U/L (normal: 8 to 38 
U/L), alanine aminotransferase (ALT) 102 U/L 
(normal: 4 to 44 U/L), total bilirubin 0.6 (normal: 0.2 
to 1.2 mg/dL), alkaline phosphatase (ALP) 236 U/L 
(normal: 50 to 190 U/L), blood urea nitrogen (BUN) 
40 mg/dL (normal: 8 to 20 mg/dL), creatinine 1.6 
mg/dL (normal: 0.6 to 1.5 mg/dL), potassium 4.4 
(normal: 3.5 to 4.3 mEq/L), lactate dehydrogenase 
(LDH) 197 U/L (normal: 20 to 240 U/L), and 
prothrombin time (PT) 11.2 seconds (normal: 8.5 to 
11.5 seconds). The chest X-ray film showed no 
active lung lesion. Computed tomography (CT) scan 
of the liver revealed liver cirrhosis and numerous 
tumors enhanced in the arterial phase and early 
wash-out in the portal phase, which were compatible 
with multiple HCC, as shown in Figure 1. 
Angiography also found multiple hypervascular 
tumors in bilateral lobes of liver. The tumor marker 
serum alpha-fetoprotein (AFP) was as high as 326 
ng/mL (normal <12 ng/ml). Under the diagnosis of 
cirrhosis, Child-Turcotte-Pugh class A, and multiple 
HCC, BCLC stage B, TACE was suggested and 
administered with epirubicin 20mg and lipiodol 5ml. 
On the 2nd day after TACE, the patient complained 
of mild epigastria, but the laboratory data revealed 
rapid elevation of serum GOT (11320), GOT (2721), 
LDH (6069), creatinine (2.6), potassium (6.0), 
phosphate (10.5; normal: 2.5 to 4.5 mg/dl), uric acid 
(14.2; normal: 2.4 to 7.2 mg/dL), decreased calcium 
(6.5; normal: 8.4 to 10.2 mg/dL) and metabolic 
acidosis (pH 7.17, normal 7.35-7.45; HCO3 7.3, 
normal 22-26 L/mmol). Other serum markers, 
including serum hemoglobin, CK, bilirubin and PT, 
were all within normal limits. ATLS was diagnosed, 
and adequate hydration, allopurinol and intravenous 
sodium bicarbonate were given immediately. 
However, oliguria, dyspnea and drowsy 
consciousness occurred on the 3rd day after TACE, 
so emergent hemodialysis was performed and an 
endotracheal tube was inserted with ventilation 
support on the same day. The laboratory data 
revealed decreased serum GOT, LDH, uric acid and 
potassium, as shown in Figure 2. Unfortunately, the 
patient’s serum bilirubin and PT levels got 
progressively worse in the next few days, and acute 
liver decompensation was considered. Refractory 
severe high anion-gap metabolic acidosis persisted in 
spite of hemodialysis, and he passed away on the 8th 
day after administration of TACE. 
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Figure 1 CT scan of the liver noted liver cirrhosis and multiple HCC 
 
 
 
 
 
 
 
 
Figure 2 The laboratory data showed the markers of tumor lysis syndrome, including GOT, LDH 
and urine acid and potassium, declined after the 2nd day, but serum bilirubin and PT levels 
increased in the next few days. 
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Discussion 
TACE was first used to treat HCC in Japan in 1974, 
but broader application of TACE began only after 
lipiodol was introduced as a drug carrier and an 
embolic agent. TACE involves mixing cytotoxic 
agents such as doxorubicin, cisplatin, mitomycin C 
with lipiodol and administering it into the feeding 
artery of the tumor. It thus has both selective 
ischemic and therapeutic effects on HCC [9]. Major 
complications of TACE have been well documented, 
including liver dysfunction, severe 
post-embolization syndrome, hepatic infarction, 
biloma formation, liver abscess, tumor rupture, 
septicemia, gastrointestinal bleeding, gallbladder 
infarction, splenic infarction, pulmonary oil 
embolism, and spinal cord injury [5]. 
ATLS is characterized by the release of 
intracellular components into the bloodstream due to 
massive lysis of malignant cells. The condition is 
associated with rapidly growing neoplasms, such as 
Burkitt's leukemia and acute lymphoblastic leukemia, 
and usually occurs after treatment with 
chemotherapy, steroids or interferon [2]. ATLS is 
less likely to occur in patients with solid tumors, 
especially HCC, which are relatively insensitive to 
anti-neoplastic therapies. Only 7 HCC cases with 
ATLS after TACE have been reported in the 
literature and they are summarized in Table 1 [1, 
3-6]. 
The pathogenesis of ATLS is related to rapid 
tumor cell destruction, which may result in the 
release of intracellular ions and metabolic 
byproducts into the systemic circulation. The risk 
factors for the development of ATLS in cancer 
patients include chemo-sensitive tumors, bulky 
tumors, large numbers of ischemic areas within the 
tumor, increased serum uric acid and impaired renal 
function prior to chemotherapy [4]. Clinically 
significant ATLS can occur spontaneously but most 
often is seen 48–72 h after initiation of cancer 
treatment [1, 4]. 
ATLS is a constellation of hyperuricemia, 
hyperkalemia, hyperphosphatemia and hypocalcemia, 
which typically develops after administration of 
aggressive combination chemotherapy for a rapidly 
proliferating neoplasm. L. Baeksgaard reported the 
biochemical characteristics of ATLS in solid tumors; 
the most common findings were hyperuricemia 
(98%) and increased LDH (96%). Less common 
findings were azotemia (93%), hyperphosphatemia 
(89%), hypocalcemia (89%), metabolic acidosis 
(83%) and hyperkalemia (73%) [10]. According to 
the Cairo-Bishop classification, ATLS is defined as a 
25% change or a level above or below normal for 
any two or more serum values of uric acid, 
potassium, phosphate, and calcium within 7 days 
after cancer therapy [11]. In our patient, all the 
laboratory parameters matched these findings. 
Paye et al. examined HCC liver resection 
specimens after TACE and found that 
post-chemoembolization cytolysis was more 
common in patients with large tumors [12]. 
Therefore, the large tumor burden is a potential risk 
factor for ATLS. Tumor necrosis, rather than damage 
to normal hepatic parenchyma, was strongly 
suggested by hyperuricemia and elevation of serum 
LDH levels. Thus, all patients with HCC undergoing 
TACE, particularly those with huge tumors, a rich 
blood supply and complete embolization, should be 
monitored closely for ATLS [3]. 
The standard preventive approach consists of 
aggressive rehydration, allopurinol, and urinary 
alkalinization following chemotherapy or other 
treatment in patients with a large tumor and 
complete embolization [4, 7]. As for the outcome of 
ALTS in solid tumors, the results have generally 
been poor, and the mortality rate is higher than that 
for hematologic malignancies [13]. However, the 
prognosis is relatively good if there is recovery of 
renal function after the uric acid level is lowered [4]. 
Although ATLS was diagnosed and treated 
immediately in our patient, he still died due to 
consecutive hepatic failure. 
Hepatic failure is considered as a more common 
cause of mortality in patients with HCC treated with 
TACE. Based on pathological studies, Paye et al. 
found that fever and hepatic dysfunction after TACE 
are mainly due to injury to the non-tumorous liver 
instead of tumor necrosis [12]. According to a 
previous study, Child-Turcotte-Pugh (CTP) class B, 
post-TACE syndrome and gastrointestinal bleeding, 
but not tumor size, were independent risk factors 
associated with liver failure in a multivariate 
analysis [14]. Another study reported the a 
pre-TACE ICG test, PT, the CTP class and lipiodol 
dosage are the most important indices to predict the 
liver damage of a patient after TACE [15]. Therefore, 
strict selection of candidates for TACE may prevent 
hepatic failure and make this treatment more feasible.
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Table 1  
Reference Sex/ Age Tumor size 
(cm) 
Underline TACE 
times 
TACE drugs ATLS onset 
(hours) 
Laboratory Data Outcome 
Cre 
(mg/dL) 
UA 
(mg/dL) 
K 
(mg/dL) 
Ca 
(mg/dL) 
P 
(mg/dL) 
LDH 
(U/L) 
urney.3 M/44 >5 n 3 DDP 60 mg/m2 8 - 10.7 7.7 10.1 11.8 2423 Death 
Burney.3 M/46 14x12 HBV,alcohol 1 n 60 - - - - - 1300 Recovery 
Sharma et al.4 M/63 14x12 HBV 1 5FU 1 g, DDP 80 mg, 
MMC 20 mg, LP 10 ml 
74 5.9 13.2 4.4 7.6 6.9 - Recovery 
Sakamoto et al.5 M/55 17x13 HBV 2 EPB 50 mg, LP 15 ml, 84 4.9 10 6.6 7.3 n 1241 Death 
iroaki et al.,6 M/77 >10 n 1 EPB 70 mg +LP 20 ml, 72 5.2 16.3 5.7 7.7 10.3 2668 Recovery 
Hsieh et al.1 F/76 >10 n 1 ADM 20 mg 48 - 16.6 5.7 6.8 - - Death 
Hsieh et al.1 M/56 >5 HBV 1 ADM 20 mg 24 - 15,1 - 6.6 4.7 - Recovery 
Our patient M/78 12x10 HBV 1 EPB 20mg + LP 5ml 24 2.6 14.2 6.0 6.5 10.5 6069 Death 
Abbreviations: 
ATLS, acute tumor lysis syndrome; HCC, hepatocellular carcinoma; HBV/HCV, hepatitis B/C virus; TACE, transarterial chemoembolization; M, male; F, female; 5-FU, 5-fluorouracil; ADM, adriamycin; DDP, cisplatin; EPB, 
epidoxorubicin; GS, gelatin sponge; LP, lipiodol; MMC, mitomycin C; Cre, creatinine; Ca, Calcium; K: Potassium; LDH, lactate dehydrogenase; P, Phosphorus; UA: Uric acid 
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However, even among HCC patients classified as 
CTP class A or B who were candidates for TACE 
therapy, a small proportion (3%) had irreversible 
liver failure [16]. Although our patient was classified 
as having CTP class A cirrhosis, acute hepatic failure 
still occurred. 
In summary, TACE may cause potentially fatal 
complications, including ATLS and hepatic failure, 
in HCC patients. Both of these conditions contribute 
directly to cytotoxic therapy and isthemic 
embolization necrosis. However, ATLS and hepatic 
failure have different presentations and mechanisms. 
Firstly, ATLS usually occurs between 48-72 hours 
after initial TACE, but hepatic failure often happens 
later. Secondly, the most important risk factor of 
ATLS after TACE in patients with HCC was the 
tumor size, but that of hepatic failure was the CTS 
class of these patients. Thirdly, the major pathologic 
damage of ATLS was at tumorous sites, whereas 
non-tumorous liver injury was found in hepatic 
failure cases. 
In conclusion, we reported an unusual case of a 
patient with multiple HCC who underwent TACE 
and had fatal complications associated with 
consecutive ATLS and hepatic failure. Recognition 
of risks and prevention are the most important steps 
in the management of these syndromes. 
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